Stockwinners Market Radar for August 05, 2021 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

18:54 EDT FTC 'disappointed' in Facebook's 'misleading' claims on consent decree - Acting Director of the Bureau of Consumer Protection Samuel Levine sent the following letter to Mark Zuckerberg concerning Facebook's "misleading" claims regarding the company's consent decree with the FTC: "I write concerning Facebook's recent insinuation that its actions against an academic research project conducted by NYU's Ad Observatory were required by the company's consent decree with the Federal Trade Commission. As the company has since acknowledged, this is inaccurate. The FTC is committed to protecting the privacy of people, and efforts to shield targeted advertising practices from scrutiny run counter to that mission. While I appreciate that Facebook has now corrected the record, I am disappointed by how your company has conducted itself in this matter. Only last week, Facebook's General Counsel, Jennifer Newstead, committed the company to "timely, transparent communication to BCP staff about significant developments." Yet the FTC received no notice that Facebook would be publicly invoking our consent decree to justify terminating academic research earlier this week. Had you honored your commitment to contact us in advance, we would have pointed out that the consent decree does not bar Facebook from creating exceptions for good-faith research in the public interest. Indeed, the FTC supports efforts to shed light on opaque business practices, especially around surveillance-based advertising. While it is not our role to resolve individual disputes between Facebook and third parties, we hope that the company is not invoking privacy - much less the FTC consent order - as a pretext to advance other aims." Reference Link

18:24 EDT Exponent VP Murray sells 6,828 common shares - In a regulatory filing, Exponent group VP Steven Murray disclosed the sale of 6,828 common shares of the company on August 3 at a price of $108.0317 per share.

17:51 EDT UPS announces new $5B share repurchase program - The company announced that its Board of Directors has approved a new share repurchase program of $5B, replacing its existing $2.1B authorization.

17:33 EDT Beyond Meat says restaurant orders more conservative amid COVID surge

17:32 EDT Benefitfocus awarded contract from State of Wisconsin - Benefitfocus announces the award of a contract supporting the State of Wisconsin's efforts to modernize its insurance administration system for the Department of Employee Trust Funds. The contract was awarded to Benefitfocus after a competitive RFP process to meet the state's need for "a new, fully-integrated, best-practices-based insurance administration system requiring minimal customizations." Benefitfocus will support the administration of core, ancillary and voluntary benefits. It will also manage COBRA administration, direct billing, consolidated billing services and analytics for more than 239,000 members of the Department of Employee Trust Funds.

17:26 EDT Beyond Meat sees return to cautionary stance from food service sector - Sees growth in food service channels to moderate in Q3. Sees early signs of return to more cautionary stance from food service sector amid COVID-19 surge from Delta variant.

17:26 EDT Zymergen names Lincoln Germain as Chief Commercial Officer - Zymergen (ZY) announced the appointments of Lincoln Germain as Chief Commercial Officer and Subodh Deshmukh as Chief Development Officer. Germain brings more than 25 years of experience in senior positions at multinational materials, agrochemical and consumer packaged goods corporations, most recently serving as Vice President and Chief Commercial Officer at Honeywell International's (HON) $3B Advanced Materials business. Deshmukh most recently served as Global Head of Product Development for Sandoz, the $10B generics division of Novartis (NVS).

17:23 EDT Dover raises quarterly dividend to 50c from 49.5c per share - This increased dividend will be paid on September 15 to shareholders of record as of August 31.

17:19 EDT Dropbox backs long-term gross margin view of 78%-80% - Also backs long-term operating margin of 28%-30% and annual free cash flow of over $1B. Comments taken from investor presentation slides.

17:08 EDT Corteva announces new $1.5B share repurchase plan - Corteva announced that its Board of Directors authorized a new $1.5B share repurchase program. This newly authorized program is in addition to $1B program announced in 2019, which the company expects to complete by the end of 2021 - more than one year ahead of its initial timeline, subject to market conditions and other considerations.

16:59 EDT Appian acquires Lana Labs, terms not disclosed - Appian announced the acquisition of Lana Labs, developer of the LANA Process Mining Platform. Lana is recognized for its expertise in complex enterprise processes, powerful AI- and machine learning-driven process analysis, easy data integration, and ease-of-use.

16:58 EDT Air Transport Services sees FY21 CapEx $550M - The company said: "ATSG's Adjusted EBITDA guidance for 2021 continues to include costs to maintain Omni Air's staffing levels, rates of pay, and benefits as required under its PSP agreements. Adjusted EBITDA, Adjusted Pretax Earnings and Adjusted EPS exclude the recognition of pandemic relief grants Omni Air received in 2021. ATSG's capital expenditures are now projected to be approximately $550 million in 2021, up $50 million from our previous guidance. The increase is primarily due to commitments to acquire five more passenger aircraft for conversion, including four Boeing 767-300s and one Airbus A321-200."

16:57 EDT Shake Shack sees FY21 domestic company-operated Shack openings 35-38

16:51 EDT Carvana reports Q2 retail units sold 107.8K, up 96% from last year. - The company states: "Q2 2021 was a landmark quarter for Carvana. We sold 107,815 retails units, our first quarter over 100k and an increase of 96% YoY. We grew revenue to $3.3 billion, our first quarter over $3 billion and an increase of 198% YoY. We achieved a company record in Total GPU of $5,120, our first quarter over $5,000, driven by company records in every underlying GPU category. We recorded our first ever quarter of positive net income of $45 million and set a company record EBITDA margin at 3.4% and company record EBITDA of $112 million. These results were accompanied by company records in cars bought from customers, the ratio of cars bought from customers relative to cars sold, and our customer-sourced ratio. Our growth in retail units combined with our even faster growth in cars bought from customers materially outpaced any sequential growth we've previously seen as a company. This resulted in constraints throughout our operational groups, indicating demand for our offering was even stronger than our results show."

16:50 EDT Expedia: July looking a lot like April, May

16:49 EDT Expedia: July started out 'a little down' vs. June

16:41 EDT Revance backs FY21 opex $375M-$390M - Revance reiterates its financial guidance provided in February 2021. The company expects 2021 GAAP operating expenses to be $375 million to $390 million and non-GAAP operating expenses, which exclude costs of revenue, depreciation and amortization and stock-based compensation to be $270 million to $285 million. Revance expects 2021 non-GAAP research and development expense to be $95 million to $105 million. With the current cash, cash equivalents and short-term investments, management projects that the company is funded into 2024.

16:41 EDT Beyond Meat sinks 5% to $116.25 after sales outlook misses estimates

16:40 EDT Cornerstone OnDemand trading resumes

16:37 EDT RLJ Lodging Trust not providing future outlook at this time - Given the continued uncertainties related to the pandemic and its impact on travel, the company is unable to provide a future outlook at this time.

16:35 EDT Expedia: July impacted 'somewhat' by Covid delta variant - Comments taken from Q2 earnings conference call.

16:30 EDT Dicerna trading resumes

16:27 EDT Brighthouse Financial announces $1B share buyback - Brighthouse Financial announced that it has authorized the repurchase of up to $1 billion of its common stock. The stock repurchase program is in addition to the $200 million stock repurchase authorization announced by the company in February 2021, under which $34 million remains as of August 4, 2021. "We are pleased to announce this new authorization as it reflects our financial strength, positions us to achieve our goal of returning $1.5 billion to our shareholders by the end of this year and supports our ongoing commitment to return capital to our shareholders," said Eric Steigerwalt, president and CEO, Brighthouse Financial. "Since the announcement of our first stock repurchase authorization in August of 2018 through August 4 of this year, we have repurchased almost $1.3 billion of our common stock, which represents a reduction of more than 31% of shares outstanding from the time we became an independent, public company."

16:23 EDT Premier board approves new $250M share repurchase program - Premier announced that its Board of Directors approved a share repurchase program under which the company may repurchase up to $250 million of its outstanding Class A common stock through the remainder of fiscal year 2022. The Board also approved a 5.3% increase in the company's quarterly cash dividend to $0.20 per share. The cash dividend will be payable on September 15, 2021, to stockholders of record as of the close of business on September 1, 2021. "The Board's approval of our new share repurchase program and increase to our dividend demonstrates our balanced approach to capital allocation - one that prioritizes investments in growth, both organically and through acquisitions, that we believe will further strengthen our ability to deliver innovative, technology-based solutions for our members and other customers," said Michael J. Alkire, President and CEO of Premier. "In addition, the Board's decision reflects the strength of our financial position, our confidence in our future and our commitment to returning capital to our stockholders."

16:20 EDT Park Hotels & Resorts not providing outlook for FY21 at this time - Given the continued economic uncertainty, travel restrictions and rapidly changing circumstances related to the COVID-19 pandemic, Park is not providing an outlook for full-year 2021 at this time. The company's ability to predict future operating results remains significantly impacted by the current COVID-19 pandemic. Park expects that the trends affecting the economy will continue to depress hotel operating results across the portfolio. While recent trends have shown signs of improvement, the economic environment continues to lack sufficient clarity at this time to provide accurate guidance.

16:18 EDT Carlisle raises quarterly dividend by 3% to 54c per share - The dividend is payable on September 1, 2021, to shareholders of record at the close of business on August 18, 2021.

16:13 EDT TripAdvisor reports June monthly unique users up 79% - April, May, and June 2021 monthly unique users on Tripadvisor-branded websites improved sequentially throughout the quarter and were approximately 59%, 71%, and 79%, respectively, of the comparable periods in 2019.

16:12 EDT Cornerstone OnDemand bought by Clearlake for $57.50 per share or $5.2B - Cornerstone OnDemand announced it has entered into a definitive agreement to be acquired by Clearlake Capital Group. Under the terms of the agreement, Clearlake will acquire the outstanding shares of Cornerstone common stock for $57.50 per share in cash. The transaction has an enterprise value of approximately $5.2B. The $57.50 per share purchase price represents a premium of approximately 31% to Cornerstone's unaffected closing stock price on June 1, the last full trading day prior to Clearlake filing a Schedule 13D in connection with the company's strategic review process. Upon completion of the transaction, Cornerstone will become a private company. The transaction, which was unanimously approved by Cornerstone's board, is not subject to a financing condition and is expected to close in the second half of 2021.

16:10 EDT Zynga's Rollic reports 1B game downloads worldwide - Zynga subsidiary Rollic announced a studio milestone of surpassing 1 billion downloads across its diverse portfolio of hyper-casual games. "We are blown away by Rollic's performance so far this year," said Bernard Kim, Zynga's President of Publishing. "Rollic is a unique publisher that is able to repeatedly publish games that surprise and delight players. They have invented a fresh approach to development that results in simple yet deeply engaging games with universal appeal."

16:09 EDT Novavax: Covid vaccine data shows increase in neutralizing antibody levels - Novavax announced preliminary data demonstrating that a single booster dose of its recombinant nanoparticle protein-based COVID-19 vaccine with Matrix-M adjuvant, NVX-CoV2373, given six months after an initial two-dose regimen, elicited a 4.6-fold increase in functional antibody titers. Additionally, functional ACE-2 binding inhibition antibodies cross-reactive with the Delta variant were more than 6-fold higher than the primary vaccination series. Complete data from the study will be submitted to a peer review publication and posted to a preprint server. The results come from an ongoing Phase 2 study in the U.S. and Australia in which select participants in the 5-microgram dose cohort received a 5-microgram booster dose 189 days after the initial two-dose regimen to examine the functional immune response. "The strong results from this study reinforce our confidence in the potential for a booster dose of NVX-CoV2373 to provide broad protection against disease, including from known and emerging variants," said Gregory M. Glenn, M.D., President of Research and Development, Novavax. "Given the evidence that natural and vaccine-induced immunity wanes over time, the continuation of our proactive clinical development program will be critical to understanding and demonstrating the effectiveness of our recombinant nanoparticle COVID-19 vaccine."

16:07 EDT Outset Medical names Nabeel Ahmed as new CFO - Outset Medical announced that Nabeel Ahmed, currently serving as Outset's Interim Chief Financial Officer, has transitioned to the permanent role of Chief Financial Officer, effective immediately.

16:03 EDT Expedia reports Q2 gross bookings $20.82B, up 667% y/y

16:02 EDT Dicerna reports 'positive' top-line results from PHYOX 2 trial - Dicerna positive top-line results from the Company's PHYOX 2 pivotal clinical trial of nedosiran, which is in development as a once-monthly treatment for primary hyperoxaluria (PH), a family of ultra-rare, life-threatening genetic disorders that initially manifest with complications in the kidneys. Nedosiran is Dicerna's lead GalXC RNAi therapeutic candidate and is designed to inhibit the hepatic lactate dehydrogenase (LDH) enzyme - an enzyme that catalyzes the final step in the glyoxylate metabolism pathway that can lead to oxalate overproduction in patients with PH. The PHYOX2 clinical trial included participants with PH subtypes 1 and 2. Nedosiran achieved the primary endpoint in the PHYOX2 trial, demonstrating a statistically significant reduction from baseline in urinary oxalate (Uox) excretion compared to placebo (pless than0.0001). The study also achieved the key secondary endpoint, with a significantly higher proportion of patients given nedosiran achieving and sustaining normal or near-normal Uox at two or more consecutive visits after Day 90 compared to placebo (p=0.0025). Uox reductions were significant in participants with PH1 while participants with PH2 (5 nedosiran and 1 placebo) showed inconsistent results in this trial. Nedosiran was generally well tolerated in the study with an overall adverse event (AE) profile consistent with previously reported data from PHYOX trials. "We believe the reduction in Uox excretion seen in patients with PH1 showed that nedosiran knocks down LDHA in the liver and reconfirms the ability of Dicerna's GalXC RNAi technology to silence disease-driving genes, de-risking our growing pipeline of GalXC product candidates," said Shreeram Aradhye, M.D., Executive Vice President and Chief Medical Officer at Dicerna. "The heterogeneity of Uox response seen in participants with PH2, despite LDHA inhibition in the liver and in contrast to prior clinical experience, suggests more complexity in the PH2 disease biology than has been previously understood and will require further evaluation."

16:00 EDT Dicerna trading halted, news pending

15:30 EDT Hywin Holdings Ltd (ADS) trading halted, volatility trading pause

14:14 EDT Diversey enters agreement to acquire Tasman Chemicals - Diversey Holdings announced it has entered into an agreement to acquire Tasman Chemicals. Tasman is an Australian manufacturer of professional hygiene and cleaning solutions to the institutional and food and beverage sectors. Commenting on the transaction, Phil Wieland, CEO of Diversey, said, "The acquisition of Tasman Chemicals provides us with a strong manufacturing footprint, allowing for greater operational flexibility and responsiveness to customer requirements. In addition, the strong reputation of Tasman will enable us to grow our position in the Australia and New Zealand markets."

13:53 EDT Coinbase enabling crypto buys with debit cards linked to Apple Pay, Google Pay - Prakash Hariramani, Senior Director - Payments & Financial Hub, Coinbase (COIN), stated in a blog post: "Fast, familiar, and secure ways to move money in and out of Coinbase are key to bringing more people into the cryptoeconomy for the first time. Today we're introducing new and seamless ways to enable crypto buys with linked debit cards to Apple Pay and Google Pay, and instant cashouts up to $100,000 per transaction available 24/7... If you already have a Visa or Mastercard debit card linked in your Apple Wallet, Apple Pay will automatically appear as a payment method when you're buying crypto with Coinbase on an Apple Pay-supported iOS device or Safari web browser. And later this fall you'll be able to buy crypto with Google Pay, a safe, simple, and secure way to pay that's used by more than 150 million people in 40 countries every month." Reference Link

13:14 EDT Veoneer says board will evaluate competing takeover bid from Qualcomm - Veoneer (VNE) confirmed that it has received a non-binding proposal from Qualcomm (QCOM) to acquire all of the outstanding shares of Veoneer at a price of $37.00 per share in cash. Veoneer said its board "will evaluate the proposal from Qualcomm consistent with its legal duties and the terms of the Magna merger agreement." On July 22, Veoneer announced that it entered into a definitive merger agreement, approved by Veoneer's board, with Magna International (MGA). "The merger agreement remains in place," the company said.

13:05 EDT Deere acquires Bear Flag Robotics for $250M - Deere & Company has signed a definitive agreement to acquire Bear Flag Robotics for $250M. Founded in 2017, the Silicon Valley-based startup develops autonomous driving technology compatible with existing machines. The deal accelerates the development and delivery of automation and autonomy on the farm and supports John Deere's long-term strategy to create smarter machines with advanced technology to support individual customer needs. Deere first started working with Bear Flag in 2019 as part of the company's Startup Collaborator program, an initiative focused on enhancing work with startup companies whose technology could add value for Deere customers. Since then, Bear Flag has successfully deployed its autonomous solution on a limited number of farms in the U.S. The Bear Flag team consists of agriculture professionals, engineers and technologists focused on autonomy, sensor fusion, vision, data, software and hardware. They will remain in Silicon Valley where they will work closely with Deere to accelerate innovation and autonomy for customers across the world.

13:01 EDT Nautilus Biotechnology jumps on revelation of 1.46M share Amazon stake - Amazon.com (AMZN) last week quietly disclosed a 1.46M share stake Nautilus Biotechnology (NAUT). When CNBC reported on stake today, shares of Nautilus jumped 47%, or $3.49, to $10.98. In a regulatory filing on July 28, showing its holdings as of June 30, Amazon disclosed owning 1.6M shares of Vital Farms (VITL), 14.3M shares of Air Transport Services Group (ASTG) and the new stake in Nautilus Biotechnology. Amazon declined comment to CNBC on whether it works with Nautilus, but its other two investments were in companies it does business with, Jordan Novet of the website points out. Nautilus says its mission is to "transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine."

12:46 EDT Nautilus Biotechnology jumps after CNBC report of Amazon stake - Shares of Nautilus Biotechnology (NAUT) jumped after CNBC reported that Amazon.com (AMZN) held a $14.7M position in the company at the end of the second quarter. CNBC cites a regulatory filing released last week for the information. Shares of Nautilus are up 47% to $10.98 following the report. Reference Link

12:32 EDT Discovery Communications trading resumes

12:25 EDT WidePoint awarded roughly $7.3M telecoms contract by ICE - WidePoint has been awarded a roughly $7.3M firm fixed price telecommunications contract with U.S. Immigration and Customs Enforcement. The contract is for IT and telecommunications for mobile device products. Reference Link

12:02 EDT Peridot Acquisition announces shareholder approval for Li-Cycle combination - Peridot Acquisition announced the results for the eight proposals considered and voted upon by its shareholders at its extraordinary general meeting on August 5, 2021. PDAC reported that all of the proposals related to the previously announced business combination agreement between PDAC and Li-Cycle were approved by the PDAC shareholders at the extraordinary general meeting.Additionally, the deadline for electing redemptions has passed with only approximately 11% of the total shares being redeemed and approximately 89% of funds will remain in PDAC's trust account as of closing. As a result, Li-Cycle expects to receive approximately $580M in gross proceeds at the time of the business combination, after giving effect to minimal redemptions. The closing of the business combination is anticipated to take place on or about August 10, 2021. Following closing of the business combination, the trading of the common stock and warrants of the combined company, called "Li-Cycle Holdings Corp.", are expected to commence trading on the New York Stock Exchange on or about August 11, 2021 under the ticker symbols "LICY" and "LICY WS", respectively.

12:00 EDT Revolve Group falls -18.6% - Revolve Group is down -18.6%, or -$13.30 to $58.04.

12:00 EDT Nevro falls -26.3% - Nevro is down -26.3%, or -$38.92 to $108.96.

12:00 EDT Ryerson rises 22.4% - Ryerson is up 22.4%, or $3.45 to $18.84.

11:09 EDT Canada Competition Bureau obtains court order to advance Rogers/Shaw probe - Canada's Competition Bureau has obtained court orders to advance its review of the proposed acquisition of Shaw Communications (SJR) by Rogers Communications (RCI), the bureau announced. "The Bureau is investigating whether the proposed transaction is likely to result in a substantial lessening or prevention of competition for services provided by the companies, including mobile wireless, wireline and broadcasting services. The orders granted by the Federal Court of Canada on July 26, 2021 and August 1, 2021, require Xplornet Communications Inc., BCE Inc., TELUS Corporation and Quebecor Inc., or 'Videotron,' to produce records and written information related to mobile wireless services that are relevant to the Bureau's investigation. The Bureau's review of the proposed transaction is ongoing," the regulator stated.

10:50 EDT Adtran sees Q3 non-GAAP gross margin 41%-43%

10:35 EDT Petco partnering with Klarna to offer 'Pay in 4' solution - Petco Health and Wellness and Klarna are partnering to offer Klarna's "Pay in 4 solution" on petco.com, across Petco's nearly 1,500 pet care centers nationwide, and the Klarna app, the companies announced. "The new payment option makes caring for the whole health of pets more accessible and flexible, giving pet parents the option to split their purchase into four interest-free payments spread over the course of six weeks," Petco said.

10:19 EDT Kulicke & Soffa jumps on stronger Q3 earnings - Shares of Kulicke & Soffa (KLIC) are on the rise on Thursday after the company reported quarterly results. The stock has more than doubled in the last 12 months. RESULTS: Kulicke & Soffa reported third quarter revenue of $424.3M and net income of $113.8M. The semiconductor equipment maker also reported earnings per share of $1.79, which was better than the expected $1.36. For the fourth quarter, the company said it expects revenue in the range of $445M-$485M, with consensus at $358.15M. PRICE ACTION: In Thursday morning trading, shares of Kulicke & Soffa has gained over 17% to $62.18.

10:02 EDT Synaptogenix signs MOU with Nemours A.I. DuPont Hospital for Fragile X Syndrome - Synaptogenix announced that it signed a memorandum of understanding with the Nemours A.I. DuPont Hospital for Children with the intention of initiating a trial to treat Fragile X with Bryostatin. Alan Tuchman M.D., Chief Executive Officer, stated, "We are very pleased to take this important step forward with the Nemours A.I. du Pont Hospital for Children, a leading institution for the treatment of childhood diseases, to partner with as we explore a second indication for Bryostatin across a new population: children and young adults. This study builds on positive preclinical studies of Fragile X by Synaptogenix scientists, most recently in collaboration with FRAXA Research Foundation, as published in a Science Reports (a Nature publication) article that extends the potential efficacy of Bryostatin from Fragile X intellectual disability to behavioral phenotypes of Autism Spectrum Disorder." Synaptogenix and the Nemours A.I. Dupont Hospital will collaborate on trial(s) of Bryostatin to treat children with Fragile X which is the most common genetic cause of intellectual disability that often includes Autistic Spectrum disorder behavioral abnormalities. Bryostatin, a lead compound of Synaptogenix, has previously been granted Orphan Drug Status by the FDA based on extensive preclinical publications authored by Synaptogenix scientists and further validated in collaboration with FRAXA Research Foundation.

10:00 EDT Sprague Resources falls -23.0% - Sprague Resources is down -23.0%, or -$5.79 to $19.35.

10:00 EDT Ping Identity rises 11.9% - Ping Identity is up 11.9%, or $2.66 to $25.02.

10:00 EDT Veoneer rises 24.5% - Veoneer is up 24.5%, or $7.66 to $38.91.

09:48 EDT OLB Group's DMint ramps up green cryptocurrency mining - The OLB Group announced DMint is planning to bring approximately one thousand cryptocurrency mining machines online this year operated by zero carbon footprint data centers. OLB has entered into an exclusive agreement to purchase all-natural gas yield from wells in Bradford, PA through Cai Energy Blockchain. The terms of the agreement enable DMint to become a vertically integrated cryptocurrency mining company. The environmental impact footprint of the cryptocurrency mining operation will be close to zero as the natural gas will be taken directly from the well heads to generate electricity. DMint has initiated the first phase of the cryptocurrency mining operation by placing purchase orders for data centers and ASIC-based Antminer S19J Pro mining computers specifically configured to mine Bitcoin. The first lot of equipment will be used to establish a proof of concept before DMint expands the number of computers in operation. As configured, it is expected that the computers purchased will have a combined computing power of approximately 100 petahash per second. Based on the mining profitability rate as of today, assuming a mining operation working at 100 petahash per second would generate $1 Million monthly recurring revenues expected starting in Q4, 2021. If the initial mining operation results are as anticipated, DMint plans to expand the number of mining computers every quarter, whereby it would potentially have the computing power of 500 petahash per second by the end of 2022.

09:47 EDT Nevro falls -22.2% - Nevro is down -22.2%, or -$32.76 to $115.12.

09:47 EDT Fiverr falls -24.6% - Fiverr is down -24.6%, or -$56.74 to $173.84.

09:47 EDT Ping Identity rises 14.2% - Ping Identity is up 14.2%, or $3.17 to $25.53.

09:46 EDT Purple Biotech expects cash to fund ongoing needs into 2024 - As of June 30, 2021, Purple Biotech had cash and cash equivalents and short- and long-term deposits of $53.4 million, compared to $60.8 million on December 31, 2020. The Company believes that its cash position will provide sufficient resources to support its currently anticipated ongoing needs into 2024.

09:40 EDT Flora Growth Corporation trading halted, volatility trading pause

09:39 EDT Galecto expects cash to fund requirements into 2H24 - Cash, cash equivalents, and marketable securities as of June 30, 2021 were approximately $138 million. We currently expect that our cash, cash equivalents and marketable securities will be sufficient to fund our operating expenses and capital requirements into the second half of 2024.

09:32 EDT Zymergen halted for volatility after jumping 39% to $11.44

09:29 EDT Wayfair says has over 31M active customers - Says Q2 came in differently than expected. Says revenue was lower than expected and profit was higher than expected. Says this quarter represented the toughest year ago comps. Says home category total addressable market will exceed $1T by 2030 in North America in Western Europe. Says average customer visits the site 9 times and browses across 29 products as part of each purchase cycle. Says building customer loyalty and gaining share of wallet. Comments taken from Q2 earnings conference call.

09:24 EDT Boxlight Invests in Clevertouch interactive displays - Boxlight announces that Guagas Municipales has implemented Clevertouch Technologies interactive displays in meetings and presentations. Before the implementation of the Clevertouch UX Pro and IMPACT Plus displays in their meeting spaces, Guagas Municipales used projectors for presentations which were inefficient and time-consuming. With the installation of Clevertouch interactive displays, the team at Guagas Municipales can facilitate meetings without wasting time or energy on extraneous cables and products, and are pleased with the innovative features such as smooth touch technology and Android OS. "Undoubtedly, the meetings improved in quality. We work on-the-fly together, something that we could not do before," stated Pablo Garcia, purchasing manager for Guagas Municipales.

09:24 EDT Blink Charging announces five-year agreement with Greenlight Communities - Blink Charging announced a five-year agreement with two five-year extensions with Greenlight Communities. After installations are completed, there will be a total of 58 Blink owned EV charging stations at Greenlight multifamily residential communities across the Phoenix metro area in Arizona. The deployments are being aided by the SRP Business EV Charger Rebate, which offers businesses up to $1,500 per networked Level 2 EV charging station. SRP, or the Salt River Project, is the electrical utility provider for the Phoenix metro and surrounding area in Maricopa County, Arizona. "We are excited to partner with developers like Greenlight Communities. With many EV drivers choosing to charge at home, Greenlight Communities is leading by example in the multifamily residential sector by providing EV charging, an important amenity to the increasing number of EV drivers in its communities," stated Brendan Jones, President of Blink. "With this agreement, which will bring Greenlight's total IQ 200 chargers up to 58, Greenlight's residents can feel confident about moving toward electric transportation alternatives. We're pleased to help Greenlight Communities in supporting green transportation and providing their EV driving residents with the convenience of this premium amenity."

09:22 EDT Grove completes acquisition of VitaMedica - Grove is pleased to announce a strong entrance into the nutraceutical space with the completed purchase of VitaMedica, a leading online seller of supplements for Surgery + Recovery, Skin + Beauty, and Health + Wellness. The closing of the acquisition will be immediately accretive to Grove, being both top line and net income positive for the company. The acquisition combines Grove's innovation in production with the extensive product line of VitaMedica, which has been recommended by thousands of doctors and served over 1 million patients. With this acquisition, the Company has taken direct aim at the vitamin + nutraceutical market in order to address the health + wellness needs of all consumers. VitaMedica stood out, not only because of its reputation and testimonials from consumers, but because of 25 years of clinical use and physician-formulated products.

09:21 EDT Skylight Health announces expansion of ClinEdge partnership - Skylight Health Group announced an expansion of their partnership with ClinEdge, one of North America's leading clinical research groups, into the state of Colorado - a key market for Skylight Health. Skylight previously announced a partnership with ClinEdge for their Study Lead Generation Services to bring industry-sponsored clinical trials to one of its primary care clinics in Massachusetts. The success of this partnership in Massachusetts has led to an expansion of the initial contract, and Skylight has now been awarded its first Colorado-based research project through ClinEdge. The research project has already initiated recruitment efforts for the study and Skylight will be responsible for consenting, enrolling, and observing patients during the 4-week research trial. Both Skylight Health and patients taking part in the study will be compensated. While this study is relatively short, Skylight Health will expect to have the study completed by the end of Q3 2021. Details of the trial are held in confidence to comply with study protocols and necessary regulatory requirements. Skylight Health expects to continue to grow its research efforts into additional markets and ClinEdge has proven to be an excellent partner for this growth effort. The Company also announces that at its Annual and Special Meeting of Shareholders held on June 29, 2021, Skylight Health's disinterested common shareholders approved the adoption of an omnibus long-term incentive plan for purposes of attracting, retaining and motivating key individuals. The Omnibus Plan permits such a number of options to be granted equal to up to 10% of Skylight Health's issued and outstanding common shares from time to time together with 3,600,000 common shares of Skylight Health available for issuance pursuant to performance share units, restricted share units, and deferred share units. Today, the Company also announces that it has issued 87,779 shares subject to TSX Venture Exchange approval pursuant to the River City Medical Associates Acquisition announced on February 4, 2021. Issued shares are restricted from trading for at least 4 months and a day from issuance.

09:19 EDT CNH Industrial's IVECO BUS wins major order to supply electric buses to Paris - The Parisian transport authority, Ile-de-France Mobilites and the city's transport operator, RATP have awarded a major European tender to IVECO BUS for the supply of its 12-meter full electric buses. This order for 180 electric buses, together with the 247 already in operation, will see IVECO BUS, a leading manufacturer of buses and coaches and a brand of CNH Industrial, become the foremost supplier of electric buses to the RATP. It marks another important step in the implementation of the Bus 2025 plan aimed at making the bus fleet of Paris, and the surrounding region more environmentally friendly. The 100% electric, zero-emissions vehicles provide a number of significant environmental benefits ranging from improved air quality, reduction of greenhouse gases and noise pollution reduction and can be recharged overnight at the depot. This full electric model is produced in the electromobility center of HEULIEZ in Rorthais, France and is part of the battery-powered bus range.

09:17 EDT Comtech awarded a $1.4M contract from domestic prime contractor - Comtech Telecommunications announced that during its fourth quarter of fiscal 2021, it was awarded a $1.4M contract for RF microwave control components from a major domestic prime contractor. These integrated microwave assemblies and protection components provide for very broad frequency coverage and are key components in an integrated electronic countermeasures system used by the U.S. military. "This contract is another example of Comtech's technical strength in delivering broadband high-power integrated assemblies for military applications and the ongoing demand for our high-power control component products," said Fred Kornberg, Chairman of the Board and Chief Executive Officer of Comtech Telecommunications Corp.

09:17 EDT Check Point announces $2B expansion of share repurchase plan - Check Point Software Technologies announced that its board of directors has authorized a $2 billion expansion of the company's on-going share repurchase program. Under the extended share repurchase program, Check Point is authorized to continue repurchasing its shares up to $325 million each quarter. As of June 30, 2021, Check Point has approximately 133 million ordinary shares outstanding. Since the beginning of the share repurchase program, Check Point has repurchased approximately 188 million shares for a total purchase price of approximately $11.1 billion. The updated plan extends the company's existing repurchase program from February 2020 which is expected to be completed during the fourth quarter of 2021.

09:16 EDT Intuitive Surgical board approves three-for-one stock split - Intuitive announced that its Board of Directors has approved a three-for-one split of the Company's common stock to be effected through an Amendment to the Company's Certificate of Incorporation. Implementation of the stock split is subject to stockholder approval of the Amendment to the Certificate of Incorporation at the Special Meeting of Stockholders, which is currently scheduled to take place on September 20, 2021. Additional details regarding the Special Meeting of Stockholders and the proposed Amendment to the Certificate of Incorporation will be included in a proxy statement scheduled to be distributed to stockholders on or about August 25, 2021. Subject to stockholder approval of the Amendment to the Certificate of Incorporation, each Intuitive stockholder of record at the close of business on the record date of September 27, 2021, will receive two additional shares for every one share held on the record date, and trading is expected to begin on a split-adjusted basis on October 5, 2021.

09:15 EDT Lenders One launches new solutions, revenue opportunities at summit - Lenders One Cooperative, managed by a subsidiary of Altisource Portfolio Solutions, begins its annual Summit in Orlando, FL on Sunday. The cooperative celebrates its continued growth and will feature a keynote speech from Frank Abagnale of "Catch Me If You Can" fame and an industry panel, including moderator Clayton Collins and panelists Andrew Bon Salle, Kathy Kraninger and Brian Montgomery. The Summit includes member-only networking sessions and education sessions designed to help members discover new opportunities and strategies for today's market and beyond. Since the last Summit in March 2020, Lenders One has welcomed 40 new members and launched initiatives to help our members improve their performance and profitability. New initiatives include: L1 Credit. L1 Credit offers credit reporting agency repository-approved full tri-merge credit reports and other Fair Credit Reporting Act related products required to manufacture a loan. Lenders One Loan Automation. This quarter the company is launching a beta version of its Lenders One loan automation technology that we refer to as LOLA.

09:15 EDT Growth Capital Acquisition Corporation (Class A Stock) trading resumes

09:14 EDT Daimler Truck, Cummins sign framework agreement for engine cooperation - Daimler Truck (DDAIF) and Cummins (CMI) announced in February that they would enter into a global strategic partnership for medium-duty engines. The details of the agreement have been established and the framework agreement has been signed by both companies. Under the strategic partnership, Cummins will invest in the further development of the medium-duty engine platform and its global production and delivery starting in the second half of the decade for Daimler Trucks & Buses. Daimler Truck AG will no longer invest its own funds in the further development of its medium-duty engines for the Euro VII emissions standard. Cummins will set up an engine production facility on the site of the Mercedes-Benz Mannheim, Germany plant for local production of medium-duty engines that meet the Euro VII emissions standard for Daimler Trucks and Buses. Production is expected to start in the second half of the decade. With this strategic partnership, Daimler Truck AG and Cummins will help maintain jobs at the Mannheim location. Cummins will use its existing footprint, production and supply chain networks in other regions. As part of the strategic partnership, Daimler Truck AG and Cummins Inc. will continue to evaluate additional opportunities for cooperation.

09:11 EDT Tremor International launches unified social data solution for advertisers - Tremor Video introduced Unified Social Data, an all-screen data solution. Powered by its partnership with ICX Media, Unified Social Data can reach more than 85M US consumer profiles from across the "walled gardens" to curate highly customizable, deterministic audiences at scale that blend social engagement data with demographic data. Unified Social Data is the latest advancement of Tremor's Data Management Platform, part of the company's end-to-end tech stack that consists of Tremor Video's DSP and Unruly's SSP. This solution is offered in a model, as advertisers can activate the solution for Connected TV and all-screen video campaigns via managed service, self-service, or private marketplaces. With the increased fragmentation in the digital ecosystem, the Unified Social Data solution helps brands: Build Niche, Custom Audience Segments and Unify Social Data Across Platforms.

09:09 EDT ViacomCBS continues to see organic execution as the right path, says CEO

09:08 EDT Ortho Clinical Diagnostics' COVID-19 antibody test authorized for Emergency Use - Ortho Clinical Diagnostics' qualitative COVID-19 Total N antibody test received FDA Emergency Use Authorization. This new antibody test is the fifth assay to receive EUA within Ortho's COVID-19 testing solutions. The test detects the individual's immune response or total antibodies to the COVID-19 virus and is intended to help clinicians understand if their patient had a recent or prior COVID-19 infection. The test offers 99.2% specificity.

09:07 EDT Berry Global to establish second manufacturing facility in Bangalore, India - Berry Global announces plans to establish a second manufacturing facility and global healthcare center of excellence in Bangalore, India. "Planned for development near Berry's existing Bangalore operation, the new facility will enable the company to extend its R&D expertise and scale up production in several key healthcare sectors: ophthalmic, nasal pumps, inhalation, and injectable administrations. The increased capacity will also enhance supply in India and throughout South Asia, addressing some of the fastest growing healthcare market geographies.," said the company. "Investing in our global healthcare business in Bangalore is a significant step in supporting our pharmaceutical, over-the-counter, and medical device customers aligned to forecasted market needs," remarked Tom Salmon, Berry Global's Chairman and CEO. "During the pandemic, we've learned that strategically placed facilities across the world provide efficient localized support for customers of any size. We believe this investment significantly benefits the India and South Asia patient populations."

09:06 EDT China Pharma's Candesartan for hypertension passes pre-application tests - China Pharma Holdings' Candesartan hypertension product passed key bioequivalence tests. The company plans to use the results of the key benchmark tests of consistency evaluation to apply for the National Medical Products Administration's approval. The NMPA is the Chinese agency for regulating drugs and medical devices - formerly the China Food and Drug Administration or CFDA. China Pharma's Candesartan was developed to treat hypertension, or high blood pressure. Lowering high blood pressure helps prevent strokes, heart attacks and kidney problems. Candesartan belongs to a class of drugs called angiotensin receptor blockers. It works by relaxing blood vessels so blood can flow more easily.

09:05 EDT Cepton Technologies to combine with Growth Capital Acquisition - Cepton and Growth Capital, a publicly traded special purpose acquisition company, announced that they have entered into a definitive business combination agreement, as well as related subscription agreements for an aggregate $58.5M private placement in connection with the business combination. Upon the closing of the transaction, the combined company will be renamed "Cepton, Inc." and is expected to be listed on the Nasdaq stock exchange under the new ticker symbol "CPTN". The transaction with Cepton enables Growth Capital to enter the lidar sector, with particular focus on ADAS in mass-market passenger vehicles, the companies said in a statement. Under the terms of the Business Combination Agreement, Cepton shareholders will receive consideration in the form of newly issued shares of Growth Capital common stock, valued based upon a Cepton enterprise value of $1.5B on a cash-free, debt-free basis. Upon closing, the combined company is expected to have an estimated equity value of approximately $1.8B, which includes approximately $231M in gross proceeds, comprised of $172.5M from Growth Capital's trust account and a $58.5M fully committed common stock PIPE, anchored by existing investor KOITO, which satisfies the contractual closing cash condition. Cash proceeds released from Growth Capital's initial $172.5M trust account after any stockholder redemptions and payment of transaction expenses and other Growth Capital liabilities will remain with the combined company, and Cepton intends to use the aggregate cash proceeds to accelerate its growth strategy, including securing additional series production design wins at other Top 10 automotive OEMs. The boards of directors for both Cepton and Growth Capital have unanimously approved the proposed business combination, which is expected to be completed in the fourth quarter of 2021.

09:04 EDT Fluidigm announces collaboration agreement with ImaBiotech - Fluidigm announced a collaboration and co-marketing agreement with ImaBiotech for service offerings and product development for Imaging Mass Cytometry. ImaBiotech is a contract research organization that offers spatial multi-omics services to the pharmaceutical research industry, specializing in precision medicine approaches to drug efficacy and toxicity evaluations, from preclinical to clinical stages. Through the acquisition of the Hyperion Imaging System, the company will be offering Imaging Mass Cytometry as one if its core technologies. ImaBiotech operates research facilities in both the U.S. and Europe in the GLP environment. "Partnering with a highly specialized imaging CRO that processes hundreds of samples per week in a GLP environment is a great opportunity for Fluidigm, and we are thrilled to partner with ImaBiotech," said Chris Linthwaite, Fluidigm President and CEO. "This collaboration will showcase the unique capabilities of Imaging Mass Cytometry in drug development and provide a foundation to develop new applications and products, enabling our technology to play a greater role in important clinical and translational research that leads to better health care decision making."

09:03 EDT Cepton announces business combination agreement with Growth Capital Acquisition

09:02 EDT Fluidigm announces co-marketing agreement with Ultivue - Fluidigm announced a co-marketing agreement with Ultivue under which the companies will offer a comprehensive portfolio of solutions for biomarker discovery and drug development. The collaboration provides researchers with end-to-end service capability for clinical and translational research work. "For example, InSituPlex technology is well-suited to identify regions of interest that may require downstream, deep profiling with Imaging Mass Cytometry. Customer access to both technologies can improve the efficiency of drug discovery programs and, in translational research, enable patient stratification to triage cases that require further investigation," the company said. "Ultivue is at the forefront of innovation to provide unique biological insights for our customers," said Mark Rees, Vice President of Corporate Development for Ultivue. "Our InSituPlex technology offers valuable profiling of the tissue and expands the depth of information possible from a single section, and thus is complementary to the high-parameter capabilities of Imaging Mass Cytometry. We believe the joint offering with Fluidigm will provide researchers with a seamless workflow that enables a far more efficient biomarker discovery and drug development process." Fluidigm is engaging in the agreement via its Therapeutic Insights Services, or TIS, unit. Mass cytometry technologies, including CyTOF , Imaging Mass Cytometry and Maxpar Direct, have been used in more than 160 clinical trials, including 10 utilizing Imaging Mass Cytometry.

09:01 EDT Qualcomm offers to acquire Veoneer for $37.00 per share in cash

09:00 EDT AppHarvest names Julie Nelson executive vice president, operations - AgTech leader AppHarvest has named Julie Nelson its executive vice president, operations. Nelson will lead efforts to scale AppHarvest's network of farms and to build manufacturing and supply chain capability to ensure efficient delivery of consistent, high-quality products to major grocers and restaurants. Nelson will play an integral role as an executive management committee member, reporting to President David Lee, and will aid in developing company strategy, establishing operations and driving efficiency to reach productivity and cost goals while ensuring quality and customer satisfaction. Nelson joins AppHarvest most recently from McKinsey & Company.

09:00 EDT Itron trading resumes

08:58 EDT ViacomCBS sees continued strong y/y streaming growth in subscription, ad unit

08:57 EDT Homology Medicines appoints Davidson as chair of scientific advisory board - Homology Medicines announced the appointment of gene therapy expert Beverly Davidson, Ph.D., as Chair of the company's Scientific Advisory Board, on which she has served since 2018. Dr. Davidson is the Director of the Raymond G. Perelman Center for Cellular and Molecular Therapeutics, the Chief Scientific Strategy Officer, and holds the Arthur V. Meigs Chair in Pediatrics at the Children's Hospital of Philadelphia. She was also recently named President of the American Society of Gene & Cell Therapy. Dr. Davidson has founded several successful biotechnology companies.

08:56 EDT Kite and Appia Bio in pact to develop allogenic cell therapies for cancer - Kite, a Gilead company , and Appia Bio , an early stage biotechnology company developing engineered allogeneic cell therapies from hematopoietic stem cells for cancer patients announced a collaboration and license agreement to research and develop HSC-derived cell therapies directed toward hematological malignancies. Under the partnership, Kite and Appia Bio will develop chimeric antigen receptor CAR-engineered invariant natural killer T cells using Appia Bio's ACUA technology platform for allogeneic cell therapy...Under the terms of the agreement, Appia Bio will be responsible for preclinical and early clinical research of two HSC-derived CAR-iNKT product candidates engineered with CARs provided by Kite. Appia Bio will receive an upfront payment, an equity investment, and additional milestone payments for a total value of up to $875 million as well as tiered royalties. Kite will be responsible for the development, manufacturing, and commercialization of the product candidates identified through the collaboration.

08:55 EDT Genius Sports announces new supplier agreement with DraftKings - Genius Sports (GENI) announced a new supplier agreement with DraftKings (DKNG) to provide its full range of official sportsbook data and content and fan engagement solutions, including a complete suite of NFL-related products. The agreement with DraftKings signifies the international adoption of official sports data across the sports ecosystem. As part of the agreement, DraftKings will leverage Genius Sports' technology to help power live experiences for millions of fans. DraftKings will also gain access to Genius Sports' proprietary, official data and live video feeds from over 170,000 events per year, including its official NFL data products, content and player acquisition and retention solutions. In April 2021, DraftKings was selected as one of the NFL's tri-exclusive official sports betting partners. In the same period, Genius Sports became the league's exclusive distributor of real-time official play-by-play statistics, proprietary Next Gen Stats data, and official sports betting data feed. DraftKings will also become one of the first betting operators to implement a full Genius Sports NFL offering, including NGS, that powers the full player lifecycle, from new acquisition to pre-and in-game engagement, as well as long-term retention. With this collaboration, DraftKings will expand its official sports data portfolio, allowing customers access to secure, authorized, and official data from leagues beyond the NFL such as the English Premier League, Liga MX and NASCAR. Through these official live streams, DraftKings users will be able to wager on hundreds of new competitions, including Argentine and Colombian soccer, and the American Hockey League.

08:55 EDT MAG Silver reports 2020 Juanicipio drill results - MAG Silver is pleased to report results from 2020 drilling on the Juanicipio Project. A total of 33 surface holes and 77 underground definition holes were completed with the primary objectives of: infilling and expanding the Valdecanas Deep Zone to optimise its extraction; and definition drilling of the upper high-grade Valdecanas Bonanza Zone where test mining has already begun and the focus for the first several years of mining in this area. Currently the 2021 drilling program is well on track with five drill rigs on surface running concurrently with continued underground definition drilling. According to Fresnillo, the project operator, mine development and mill construction continue to advance on budget and on schedule to commence mill commissioning in Q4 2021. Selected highlights of the 2020 drilling program are presented below in Table 1. Figure 1 shows the significant increase in drillhole intercept density and growth of the Valdecanas Vein, especially the Deep Zone, since the 2017 PEA. Figure 2 shows the growth of the Anticipada vein since the end of 2016. A complete set of tables by vein of the 2019 drilling results are available here along with a new 3D video displaying the entire Valdecanas Vein system, available here. The 2020 drilling program successfully: Confirms, and allows modeling with greater detail and confidence of the high-grade silver resource within the upper parts of the Valdecanas Bonanza Zone where the first several years of mining will occur; Confirms, expands, and allows improved modeling of the continuous wide mineralization of the Valdecanas Deep Zone; and, Confirms, expands, and allows improved modeling of the ever-growing Anticipada Vein.

08:53 EDT Hill International awarded five-year program management contract - Hill International announced it was awarded a contract to provide program management services for the Miami-Dade County Aviation Department's $5B Capital Improvement Program. The program encompasses Miami International Airport as well as all the County's executive and general aviation airports and will support modernization projects over the next 15 years. Hill's contract is for the initial five years of the program, with the potential to execute two additional five-year extensions. "The pandemic certainly slowed growth in the region, but as air travel returns there is building pressure to resume and accelerate that growth," concludes Hill's Chief Executive Officer Raouf Ghali. "MDAD's program will take advantage of the pressure to realize these new and improved facilities and put Miami-Dade's airports ahead of the curve, as efficiently and cost-effectively as possible."

08:52 EDT Blackwells opposes sale of Monmouth Real Estate to Equity Commonwealth - Blackwells Capital, LLC, an alternative investment management firm that, together with its affiliates, owns 4.17% of Monmouth Real Estate Investment Corporation issued a letter to its fellow shareholders urging them to vote against the proposed sale to Equity Commonwealth. The letter read in part, " As Monmouth's fourth largest shareholder, we are writing to urge you to vote "AGAINST" the proposed transaction with EQC. The proposed all-stock transaction is banefully flawed and, we believe, is intended to benefit the Landy family in a manner different from other shareholders. Our view is that the Landys' contempt for the democratic shareholder process, an overriding desire to protect themselves from criticism and accountability, and a 'win at all cost' attitude towards preserving employment and financial positions in Monmouth have guided their every decision. As a result, the Landys shaped a sale process that attempts to force Monmouth shareholders to accept a deal that values each share they hold at only $17.25 based on yesterday's closing price of EQC. Meanwhile, Monmouth shares are currently worth $18.88 per share. Monmouth has been a laggard in its industry for many years, and for more than five years has consistently ranked among the poorest performing industrial REITS in America.3 In 2019, Monmouth's governance was rated as among the worst of any publicly listed industrial REIT, and was also among the worst even among all REITs more generally.4 Blackwells began its engagement with Monmouth late last year with the intention of unlocking years of suppressed value. It came as little surprise to Blackwells, when in December of 2020 upon submitting an all-cash proposal to acquire Monmouth, we were met with intransigence and indignation. The Landy family scrambled to find an outcome addressing their needs, while Blackwells nominated candidates to run for election to Monmouth's Board at this year's Annual Meeting, which is typically held in June. No Annual Meeting was held, and the Monmouth Board continues to evade its responsibility to hold one. A public company cannot be run this way...From the flop of a sale process, to slipshod valuation gymnastics, and poorly managed competing offers, the current Board has failed its shareholders. The result: a binding agreement that exposes Monmouth shareholders to a significant breakup fee in return for an EQC offer that today values your Monmouth shares at substantially less than every bona fide all-cash offer received during the entire sale process. The compelling alternative: reject the EQC transaction and elect new directors who are capable of unlocking the value of your Monmouth shares. Monmouth's industrial properties have great durable value. We are confident that through a new process, overseen by a committee of the Board that is focused, that is committed to creating value for the public shareholders and that can skillfully negotiate conflict-free and pressure-free, Monmouth shareholders will garner the consideration they deserve. Once the EQC transaction is voted down, Monmouth must immediately call its overdue Annual Meeting to allow shareholders to elect new directors to the Board, ones who are capable of ensuring that the interests of all shareholders - not just the Landy family - are fully protected, and that value for Monmouth's shareholders is maximized. Please join us in voting "AGAINST" the proposed transaction with EQC, to begin a more successful chapter."

08:50 EDT Sportsnet, Firstlight Media, Deltare partner to enhance streaming experience - Sportsnet has partnered with Deltatre and Firstlight Media to reimagine and relaunch SN NOW - Canada's sports streaming service - to "deliver the best fan experience, highest quality streaming, and most personalized and engaging viewing features available anywhere in sports media," the company said. "By collaborating with these global technology powerhouses, Sportsnet will redesign SN NOW with a suite of integrated next-generation OTT features and a refreshed user interface, on the Firstlight Media platform, powered by Microsoft Azure. Phased in enhancements will include greater stream quality and reliability, personalized content offerings, advanced stats overlays, and other innovative features to drive the ultimate sports viewing experience," the company added. Firstlight Media will build the technology foundation for the new SN NOW. Sportsnet will unveil the first phase of the all-new SN NOW this Fall with additional development phases planned going forward.

08:50 EDT Meta Materials to 'indirectly' acquire Nanotech Security for C$90.8M - Meta Materials announced the signing of a definitive agreement for META to indirectly acquire Nanotech Security (NTSFF), a developer of secure and visually memorable nano-optic security features that provide anti-counterfeiting solutions used in the government and banknote and brand protection markets, in an all-cash transaction at C$1.25 per Nanotech common share, for a total value of approximately C$90.8M. The addition of Nanotech's highly experienced manufacturing group, its nanophotonics R&D teams and its well-established origination and conversion capabilities is expected to significantly expand and accelerate META's design-to-production roadmap and extend its leadership position in commercializing metamaterials. Nanotech brings state of the art electron beam lithography , high-volume, roll-to-roll nanoimprint lithography and nano-coating production equipment, with current capacity exceeding 7 million square meters per year, at significantly lower production costs compared to semiconductor processes. In-house EBL capabilities are expected to significantly increase META's capacity for new customer engagements and shorten material selection programs. META's proprietary roll-to-roll volume holographic technology, as well as its Rolling Mask Lithography ) and related design know-how and intellectual property, offer additional proprietary security applications to help expand Nanotech's leadership position in high-volume highly customizable security films.

08:47 EDT Boxed announces $45M secured credit facility - Boxed announced that it has entered into a new $45 million secured credit facility provided by funds and accounts managed by BlackRock. The New Credit Facility will mature on August 4, 2025, and is secured by all of the assets of Boxed and its subsidiaries, subject to customary exceptions. On June 13, 2021, Boxed and Seven Oaks Acquisition Corp., a publicly-traded special purpose acquisition company, entered into a definitive agreement relating to the business combination that would result in Boxed becoming a public company upon the closing of the transaction.

08:46 EDT Eneti to acquire Seajacks in share, cash transaction - Eneti announced that one of its wholly-owned direct subsidiaries entered into a binding agreement with Marubeni Corporation, INCJ, Ltd. and Mitsui O.S.K., Lines under which Eneti will acquire 100% of Atlantis Investorco Limited, the parent of Seajacks International Limited, for consideration of approximately 8.13 million shares, $299 million of assumed net debt, $74 million of newly-issued redeemable notes, and $12 million of cash. The share consideration is comprised of 7,433,031 common shares and 700,000 preferential shares in Eneti, subject to closing adjustments. The preferred shares hold a liquidation preference, will receive regular dividends, are without voting rights, and will be converted to common shares. In order to satisfy a portion of Seajacks' debt, the Sellers will receive cash consideration of $12 million. At closing, the Company will issue subordinated redeemable notes totaling $73,599,849. Eneti will also assume $87,650,000 of subordinated, non-amortizing debt due in September 2022 and owed to financial institutions with guarantees provided by the Sellers. The remaining existing secured debt of approximately $267,532,868 will be satisfied in full upon closing of the transaction. Upon closing, existing Eneti shareholders will own 58% of Eneti and the Sellers will own 42%. As a result of the transaction, Mr. Hiroshi Tachigami of Marubeni Corporation, and Mr. Peter Niklai of INCJ, Ltd. will join the Eneti Board of Directors. As part of the transaction, Eneti has received a commitment from ING Bank N.V. for a senior secured non-amortizing revolving credit facility of up to $60 million. The credit facility, which includes sub-limits for performance bonds, has a final maturity of August 2022 and bears interest at LIBOR plus a margin of 2.45% per annum, and is subject to certain conditions precedent and the execution of definitive documentation. Based upon projected earnings from existing and projected employment, Seajacks is expected to have EBITDA in 2021 in the region of $125 million. EBITDA projections for 2021 are based on $224 million of projected revenues, of which 89% are revenues relating to existing contracted employment. In 2022, Seajacks has firm revenue of approximately $118 million through employment contracts on 63% of the available days for the "Seajacks Scylla" and "Seajacks Zaratan". Seajacks was founded in 2006 and is based in Great Yarmouth, UK. It is the largest owner of purpose-built self-propelled WTIVs in the world and has a track record of installing wind turbines and foundations dating to 2009. Seajacks' flagship, NG14000X design "Seajacks Scylla", was delivered from Samsung Heavy Industries in 2015, and it is currently employed in Asia. Seajacks also owns and operates the NG5500C design "Seajacks Zaratan" which is currently operating in the Japanese market under the highly coveted Japanese flag, as well as three NG2500X specification WTIVs which are employed in the North Sea market. As a result of the transaction, provisions in the employment contracts of certain Eneti executives will trigger payments in the aggregate amount of $30 million. In order to avoid adverse US tax consequences, the Company is required to incur these costs at the time of the transaction. The U.S. senior executive officers receiving these payments have agreed not to receive salaries for a period of three years and bonuses for a period of four years.. The transaction, which has been approved by the Boards of Directors of Eneti and the Sellers, is expected to close by the middle of the third quarter of 2021. BofA Securities, Inc. and ING Bank N.V. are serving as financial advisors to Eneti for the transaction and Slaughter and May, Seward & Kissel LLP and CMS Cameron McKenna Nabarro Olswang LLP are acting as its legal advisors. Pareto Securities Pte Ltd. is serving as Seajacks' financial advisor and Sherman & Sterling LLP is acting as its legal advisor. Additionally, the Company signed binding agreements with counterparties in Japan to transfer the existing lease finance arrangements of the SBI Tango, SBI Echo, and SBI Hermes, Ultramax bulk carriers built in 2015, 2015, and 2016 respectively, and SBI Rumba and SBI Samba, Kamsarmax bulk carriers built in 2015, to affiliates of Scorpio Holdings Limited for consideration of $16 million. This transaction was approved by the Company's independent directors in January 2021. The final vessel was delivered in July 2021, and marks the conclusion of the Company's exit from the dry bulk sector announced on December 20, 2020.

08:44 EDT ViacomCBS has extended contract with Trey Parker and Matt Stone through 2027 - The deal will see "South Park" on Comedy Central through its 30th season.

08:43 EDT HTG Molecular announces commercial launch of HTG Transcriptome Panel - HTG Molecular Diagnostics announced the commercial launch and availability of its HTG Transcriptome Panel, designed to measure approximately 20,000 mRNA targets using the HTG EdgeSeq technology, in the U.S. and Europe. While HTG received its first orders for this product from Early Adopter Program collaborators in June 2021, the HTG Transcriptome Panel is now commercially available to all HTG customers for purchase in kit form or as a service in HTG's VERI/O laboratory. The HTG Transcriptome Panel is currently for use with the Illumina sequencing platforms. In addition to the launch of its HTG Transcriptome Panel, HTG has commercially released for immediate availability HTG EdgeSeq Reveal version 4.0.0, adding additional features and software functionalities to support, among other things, data analysis for the HTG Transcriptome Panel. Byron Lawson, Senior Vice President and Chief Commercial Officer added, "We have seen significant interest in and anticipation for our HTG Transcriptome Panel since we introduced the panel to our EAP collaborators in late 2020. We will continue to work with our EAP collaborators to highlight real-world applications using the panel to answer complex research questions in oncology, immunology, and other fields. We are very pleased with the response this product has already received from EAP and non-EAP customers alike and look forward to beginning work on several planned programs with additional customers who have been waiting for our final product release to begin studies. We look forward to the additional opportunities that we believe the HTG Transcriptome Panel will create for HTG as our sales teams begin to broadly sell the product with the commercial release for sale in the U.S. and Europe."

08:41 EDT ViacomCBS: Average age on Paramount+ continues to get younger, says Bakish

08:40 EDT Stryve Foods expands into new category with Stryve Nutrition - Stryve Foods announced the introduction of its new Stryve Nutrition products. The new category of products is led by the launch of Stryve Collagen protein powder in Chocolate, French Vanilla, Superfruit and Unflavored and Stryve Bone Broth protein powder in Chocolate and Vanilla flavors, which is expected to be available in the coming weeks. All Collagen and Bone Broth products are non-GMO, all-natural, gluten-free, soy-free, and dairy-free. A natural extension and complement to Stryve's popular healthy air-dried meat snacking products, Stryve Nutrition's Collagen and Bone Broth protein powders are functional foods also packed with protein and contain no sugar and nothing artificial. Stryve Nutrition's Collagen Protein products are available at www.stryve.com and are expected to be coming soon to Amazon and select retailers. Stryve Nutrition's Bone Broth Protein products will be available in the coming weeks at www.stryve.com, and are also expected to be coming soon to Amazon and select retailers.

08:37 EDT Marimed, Emack & Bolio's collaborate for cannabis infused ice cream - MariMed announced a joint collaboration with the legendary Boston ice cream brand Emack & Bolio's. MariMed and the ice cream magicians at Emack & Bolio's will create a line-up of cannabis-infused vegan and dairy ice cream in outrageous flavors. The ice cream will contain MariMed's superior formulations that include the same full spectrum of natural cannabinoids and terpenes from whole plants as are used in MariMed's award-winning brands, such as Betty's Eddies and K Fusion. This innovative new category of cannabis products is expected to debut in Massachusetts this year, followed by launches in other legal cannabis markets.

08:37 EDT ViacomCBS expects PlutoTV to 'comfortably' generate over $1B in revenue in 2021

08:36 EDT ViacomCBS had 'historic' linear TV upfront, says CEO

08:35 EDT Party City sees FY21 CapEx $80M-$90M

08:34 EDT Harsco extends contractual relationship with Arkansas Steel Associates - Harsco Corporation announced that its Harsco Environmental division has successfully entered into a new multi-year services contract with existing customer, Arkansas Steel Associates LLC, based in Newport, Arkansas. This new agreement extends Harsco Environmental's prior seven-year relationship for another seven years, cementing Harsco Environmental as ASA's preferred service provider for slag and scrap management, slag processing, metal recovery and refractory services.

08:32 EDT Oxford Lane estimates July NAV $6.68-$6.78 - Management's unaudited estimate of the range of the NAV per share of our common stock as of July 31, 2021 is between $6.68 and $6.78. This estimate is not a comprehensive statement of our financial condition or results for the month ended July 31, 2021. This estimate did not undergo the Company's typical quarter-end financial closing procedures and was not approved by the Company's board of directors. We advise you that our NAV per share for the quarter ending September 30, 2021 may differ materially from this estimate, which is given only as of July 31, 2021. As of July 31, 2021, the Company had approximately 111.8 million shares of common stock issued and outstanding.

08:29 EDT BioVie announces first patient enrolled in Phase 3 study of NE3107 - BioVie announced that the company has enrolled the first patient into the NM101 Phase III clinical study testing NE3107 for the treatment of Alzheimer's Disease. The NM101 study is a Phase 3, randomized, double blind, placebo-controlled, US multicenter study of NE3107 in 316 subjects with mild to moderate AD. In addition to conventional cognition, memory, functional, behavioral and imaging end points, NM101 will assess measures of glycemic control, brain glucose utilization and systems dysregulation. The study aims to have data readout by the end of 2022. "NM101 is the first randomized, double blind, placebo-controlled Phase 3 trial conducted by any company to test a potentially disease modifying anti-inflammatory insulin sensitizer compound in subjects with mild to moderate AD," said Cuong Do, Chief Executive Officer of BioVie. "In prior animal studies and Phase 1 and 2 human clinical studies, NE3107 generated data supporting reduced neuroinflammation and insulin resistance, both of which are recognized as important players in AD pathology." Neuroinflammation and insulin resistance are associated with cognitive decline associated with Alzheimer's. NE3107's potential to inhibit neuroinflammation and insulin resistance forms the basis for the hypothesis that it may impact cognitive decline in Alzheimer's patients.

08:26 EDT Prometheus announces chairman of the board's unexpected passing - Prometheus Biosciences announced that its Chairman of the Board, Tadataka Yamada, M.D., KBE, passed away unexpectedly on August 4, 2021.

08:25 EDT Meta Materials Inc trading halted, news pending

08:24 EDT Cogent increases quarterly dividend to 80.5c per share - Cogent approved an increase of 2.5c per share to its regular quarterly dividend for a total of 80.5c per share for Q3 as compared to 78c per share for Q2- Cogent's thirty-sixth consecutive quarterly dividend increase.

08:24 EDT Bitfarms mined 391 new bitcoin during July - Bitfarms announces a Bitcoin production update and the announcement date of its second quarter 2021 financial results. Mined 391 new Bitcoin during July 2021, Bitfarms' largest monthly production rate achieved in 2021 and approximately 96% more than its mining production in January 2021. The Company is currently mining between 121/2 and 131/2 Bitcoin each day. Mined 1,748 Bitcoin in the first seven months of 2021, the largest number of Bitcoin mined in North America as reported by publicly traded miners. Deposited 1,678 Bitcoin into custody through August 1, 2021, representing approximately 96% of the Company's Bitcoin production this year and valued at approximately US$69.8 million based on the July 31st closing price of US$41,626.

08:23 EDT Wheels Up names Gene McKenna as Chief Product Officer - Wheels Up (UP) announced the appointment of Gene McKenna as Chief Product Officer. . McKenna will oversee the entire Product portfolio - developing and driving the vision, roadmap and strategy to accelerate the company's growth. McKenna joins Wheels Up with 18 years of product management experience and a decade of software engineering experience. During his career, he founded and sold two internet companies in the events and travel industries, and has held leadership positions at large corporations, including Acxiom Digital and Groupon (GRPN).

08:21 EDT E2open, Vizient announce strategic relationship - E2open announces a strategic relationship with Vizient, the largest healthcare performance improvement company in U.S., to develop a new platform to increase trust, transparency and predictability for its member health systems. E2open and Vizient entered into a strategic relationship to facilitate the rapid development of a cloud-based, multi-party collaboration platform that enables end-to-end visibility between participating healthcare providers, distributors and suppliers. The platform will enable timely insights into forecast, inventory availability, transportation, and consumption of goods with proactive management alerts for disruptions and imbalances to improve availability of healthcare products. The healthcare resiliency platform will be enabled by configuring E2open's technology and network for the specific product flows that are unique to the healthcare industry. The healthcare resiliency platform will be available to Vizient's membership, which includes acute care providers, academic medical centers and ambulatory care providers, as well as healthcare suppliers.

08:18 EDT KVH Industries receives $7.9M fiber optic gyro order from Escribano - KVH Industries announced that it has received a $7.9M fiber optic gyro order from Escribano, a Spanish defense contractor, for its new Guardian 30 remotely controlled turret. The Guardian 30 turret was recently chosen by the Spanish Ministry of Defense for the Spanish Army's VCR 8x8 Dragon wheeled combat vehicle. KVH's DSP-1750 FOG will provide stabilization for the Guardian 30 turret. KVH's shipment of FOGs to Escribano is expected to continue through 2025. Shipments increase annually over the term of the order, with a small portion scheduled for delivery in 2021 and the substantial majority of shipments scheduled for delivery after 2022. "We are thrilled that Escribano has chosen our fiber optic gyros for this major remote weapons systems program," says Sean McCormack, senior director of global inertial systems sales for KVH. "The DSP-1750 has proven its reliability in a wide range of applications for many years and continues to be the gyro of choice for platforms needing a combination of high performance and compact design."

08:17 EDT U.S. Physical Therapy boosts dividend to 38c per share - In response to the Company's strong performance thus far in 2021 and confidence in its future performance, the Company's Board of Directors increased the Company's quarterly dividend on August 3, 2021, from $0.35 per share to $0.38 per share, an increase of 8.6%. The Board of Directors subsequently declared a quarterly dividend of $0.38 per share which will be paid on September 17, 2021 to shareholders of record as of August 20, 2021.

08:16 EDT Nuwellis to make renal therapy device for children, babies under $1.7M NIH grant - Nuwellis plans to develop a fully integrated pediatric continuous renal replacement therapy device designed to provide care for small babies and children. The new device will build on the existing technology of the company's Aquadex SmartFlow system, and will be funded in part by a $1.7M grant from the National Institutes of Health, or NIH. Nuwellis has partnered with Minneapolis-based research and development firm Koronis Biomedical Technologies, the grant recipient, to design and develop a custom pediatric product that will enable clinicians to better care for babies with limited kidney function. CRRT machines are fluid management devices designed to aid or replace kidney function by removing excess fluid and toxins when the patient's kidneys are unable to support the demands of the body. The new device will be designed to lower the potential complications, enhance the functionality of traditional CRRT machines, and incorporate technologies that are needed to address issues relevant to small children. Aquadex SmartFlow ultrafiltration is currently approved for adults and pediatric patients weighing 20 kg or more, and works to remove excess fluid to alleviate kidney burden.

08:14 EDT Centene announces actions to protect members, employees from Covid-19 - Centene announced it is taking additional steps to further protect members and employees from COVID-19, to educate its key stakeholders about the benefits of the vaccine, and to prepare for anticipated vaccine and testing requirements for companies that hold federal contracts. Earlier this week, the company requested all employees to provide proof of their COVID-19 vaccination as soon as possible. Employees who do not provide proof of vaccination will be required to participate in regular COVID-19 testing and wear masks at all times while in company offices. In addition, Centene is delaying its first phase of the company's return to in-person engagement from September 13, 2021, until October 18, 2021, providing additional time for Centene employees to be vaccinated. Centene will also require vaccination as a general condition of employment for all new employees beginning October 1, 2021, as well as require essential business contractors and subcontractors to provide vaccination attestation prior to entering Centene offices. As an additional measure of care for our members, the company will require employees conducting in-home visits or clinical facility visits with direct member interaction to be fully vaccinated. Centene's additional guidance aligns with the federal government's announcement that all federal workers and onsite contractors must be vaccinated or be regularly tested, a requirement that is anticipated will soon apply to all companies that hold federal contracts. As a leading healthcare company with contracts related to the federal government, Centene is committed to following similar guidelines.

08:13 EDT Best Buy commits up to $10M in Brown Venture Group's inaugural fund - Brown Venture Group, a venture capital firm formed to fund Black, Latino and Indigenous technology entrepreneurs, announced that Best Buy has committed up to $10M to its inaugural fund. The commitment by Best Buy builds on its recent announcement that it will spend at least $1.2B with BIPOC and diverse businesses by 2025 with a focus on leaders in the tech industry.

08:10 EDT Rite Aid, Shipt announce same-day delivery partnership - Same-day delivery service Shipt and Rite Aid announced a partnership to bring same-day delivery of health and wellness products to Rite Aid's retail footprint across 17 states. Customers can order from more than 2,000 Rite Aid locations through the Shipt marketplace, with delivery to their door in as soon as one hour. To kick off the partnership, starting Aug. 5 through Aug. 12, customers will receive $10 off when they spend $50 on their first Rite Aid order.

08:04 EDT PPL Corp. announces plan to repurchase $500M in shares in 2021 - The company said it expects to repurchase approximately $500M in common shares by the end of 2021 and will continue to assess opportunities to deploy the remaining proceeds.

08:00 EDT OneWater Marine completes acquisition of Stone Harbor Marina - OneWater Marine announced that it has completed the previously announced acquisition of Stone Harbor Marina. Stone Harbor enhances the company's presence in the northeastern U.S. and expands new and pre-owned boat sales, storage, service and repair, and finance and insurance offerings. "We are elated to officially welcome Tom Russell and the Stone Harbor team into the OneWater family. Our acquisition strategy and proven history of integration continue to drive growth in the business and value for our shareholders," said Austin Singleton, Chief Executive Officer for OneWater.

07:58 EDT Quanta's Medolife Rx to participate in Tony Hawk's Vert Alert event - Medolife Rx which is a majority owned subsidiary of Quanta, announced that it will join the highly anticipated "Tony Hawk's Vert Alert" competition. This event will feature the most elite current skaters and returning Olympians, top skating legends, such as Tony Hawk, as well as members of the famous Bones Brigade. The event will be held at the Utah State Fairgrounds in Salt Lake City on August 27 and 28. This is the first major audience-attended skateboarding competition since the beginning of the pandemic, which is looking to attract over 8,000 attendees over the two days of competition.

07:56 EDT AnPac Bio, Roche Pharmaceuticals China enter cooperation agreement - AnPac Bio-Medical Science announced that Announced that AnPac Bio and Roche Pharmaceuticals China have entered into a cooperation agreement to explore novel healthcare and medical solutions and collaboration models in early cancer screening, early diagnosis, and early treatment, through leveraging both parties' advantages and sources. AnPac Bio and Roche will jointly explore personalized product lines and solutions consisting of early cancer screening, early diagnosis and early treatment. The cooperation will target general population for early cancer screening, hospital diagnosis, and precision medicine through therapy selection testing. According to the agreement, both parties plan to utilize AnPac Bio's Cancer Differentiation Analysis cancer detection technology and Roche's FoundationOne CDx to form a full solution, under which customers assessed with a high cancer risk level using CDA tests and later diagnosed with cancer will receive CDx precision medicine test and service for therapy selection. The collaboration aims to benefit general population via reducing medical costs and saving more patients' lives.

07:49 EDT Dyne Therapeutics expects cash to fund requirements into 2H24 - Cash, cash equivalents and marketable securities were $435.6 million as of June 30, 2021, which is anticipated to fund operations into the second half of 2024.

07:46 EDT Cabaletta Bio sees cash, cash equivalents to fund operations into Q4 of 2022 - As of June 30, 2021, cash, cash equivalents and investments totaled $102.8M, compared to $108.7M as of December 31, 2020. During the quarter, the company received net proceeds of approximately $7.7M pursuant to its at-the-market stock offering program.

07:45 EDT Xoma expects cash to fund operations for multiple years - On June 30, 2021, XOMA had cash of $78.9 million. The Company ended December 31, 2020, with cash of $84.2 million. On April 12, 2021, XOMA announced the closing of its Depositary Shares Offering and the exercise of the underwriters' option, which resulted in approximately $38.0 million after deducting underwriting discounts and commissions, but before expenses. On April 15, 2021, the Company paid its first dividend on Series A Cumulative Perpetual Preferred in the amount of $0.71875 per share. The Company continues to believe its current cash position will be sufficient to fund XOMA's operations for multiple years.

07:42 EDT Intellia Therapeutics expects cash to fund requirements beyond next 24 months - Intellia expects that its cash, cash equivalents and marketable securities as of June 30, 2021, along with the proceeds from the July 2021 public offering of common stock, will enable the Company to fund its robust R&D plans, anticipated operating expenses and capital expenditure requirements beyond the next 24 months. This expectation excludes any strategic use of capital not currently in the Company's base-case planning assumptions.

07:40 EDT Wave Life Sciences expects cash to fund requirements into 2Q23 - As of June 30, 2021, Wave had $143.8 million in cash and cash equivalents as compared to $184.5 million as of December 31, 2020. The decrease in cash and cash equivalents was mainly due to Wave's year-to-date net loss of $81.2 million, partially offset by the receipt of $30.0 million in research support funding from Takeda under the company's collaboration in the second quarter and $13.1 million in year-to-date net proceeds under Wave's at-the-market equity program. Wave expects that its existing cash and cash equivalents, together with expected and committed cash from its existing collaboration, will enable the company to fund its operating and capital expenditure requirements into the second quarter of 2023.

07:38 EDT Amicus announces upcoming milestones by program - Galafold Oral Precision Medicine for Fabry Disease: continue revenue growth in 2021, EU label expanded to cover adolescent population, continue geographic expansion, registry and other Phase 4 studies. AT-GAA for Pompe Disease: completed the BLA and NDA submissions in 3Q21; EU MAA submissions to be completed in 2H2021 and ongoing supportive studies, including pediatric and extension studies. Gene Therapy Portfolio: advance manufacturing activities and regulatory discussions for the CLN6 Batten disease gene therapy program to enable dosing of additional patients with GMP clinical grade material; reported initial data from the CLN3 Batten disease gene therapy Phase 1/2 study; advance manufacturing activities and regulatory discussions to enable dosing additional patients with GMP clinical-grade material; continue to progress IND-enabling work in both Pompe and Fabry gene therapies; disclose additional preclinical data and potential IND candidate declarations across multiple preclinical programs; and manufacturing advancements and updates across the portfolio.

07:35 EDT Aclaris Therapeutics announces upcoming milestones - Aclaris plans to progress ATI-450 into a Phase 2b trial in moderate to severe rheumatoid arthritis in the fourth quarter of 2021; Aclaris plans to progress ATI-1777 into a Phase 2b trial in moderate to severe atopic dermatitis; and Submission of Investigational New Drug Application for ATI-2138 is expected in the second half of 2021.

07:30 EDT Score Media and Gaming trading resumes

07:24 EDT Jounce Therapeutics expects cash to fund requirements through 3Q23 - Based on its current operating and development plans, Jounce continues to expect gross cash burn on operating expenses and capital expenditures for the full year 2021 to be approximately $95.0 million to $110.0 million. Given the strength of its balance sheet, Jounce expects its existing cash, cash equivalents and investments to be sufficient to enable the funding of its operating expenses and capital expenditure requirements through the third quarter of 2023.

07:22 EDT Kala Pharmaceuticals sees cash funding operations for at least two years - As of June 30, 2021, Kala had cash, cash equivalents and short-term investments of $149.6 million, compared to $153.5 million as of December 31, 2020. This decrease primarily reflects cash used in operations, largely offset by net proceeds of $40.7 million received from sales of common stock under Kala's at-the-market offering program in the six months ended June 30, 2021, and the release of $10 million in restricted cash in connection with Kala's repayment of its credit facility with Athyrium following its entry into a loan agreement with Oxford Finance. Kala anticipates that its cash resources as of June 30, 2021, together with anticipated revenue from EYSUVIS and INVELTYS, will enable it to fund its operations for at least two years.

07:19 EDT Athenex expects cash, cash equivalents to fund operations into Q4 of 2022 - As of June 30, 2021, the company had cash and cash equivalents, restricted cash and short-term investments of $146.7 million. Given uncertainty stemming from the CRL for oral paclitaxel, the company identified and adopted certain cash conservation measures. Considering these initial measures, and based on our current operating plan, the company now expects that its cash and cash equivalents, restricted cash and short-term investments as of June 30, 2021, will enable it to meet its current operational liquidity needs and fund operations into 4Q 2022. The company is also affirming the guidance it provided on May 6, 2021, as it currently expects its product sales in 2021, excluding any royalties from Klisyri, to be in line with 2020 levels.

07:16 EDT Aravive expects cash, cash equivalents to fund operations into H2 of 2022 - As of June 30, 2021, cash and cash equivalents were $75.4M, compared to $60.5M as of December 31, 2020. The company expects that its current cash and cash equivalents will be sufficient to fund its operating plans into the second half of 2022.

07:14 EDT Autolus Therapeutics expects cash to provide runway into H1 of 2023 - Cash at June 30, 2021, totaled $216.4M, as compared to $239.0M at March 31, 2020. Autolus estimates that its current cash on hand will provide the company with a cash runway into H1 2023.

07:09 EDT ViacomCBS reports Q2 streaming revenue up 92% - Reports Q2 advertising revenue up 24%. Global streaming subscribers rose to more than 42M, adding 6.5M subscribers in the quarter.

07:06 EDT Chimerix announces expected upcoming milestones - Negotiation of a smallpox procurement agreement for TEMBEXA; completion of TEMBEXA drug product manufacturing to support potential shipments up to $100M for U.S. national preparedness; and efficacy analysis by blinded independent central review of 50-subject registration cohort of ONC201 in recurrent H3 K27M-mutant glioma.

07:04 EDT Passage Bio expects cash balance to fund operations for next 24 months - Cash, cash equivalents and marketable securities were $407.8M as of June 30, 2021, as compared to $304.8 million as of December 31, 2020. The company expects current cash and cash equivalents to fund operations for at least the next 24 months.

07:02 EDT Growth Capital Acquisition Corporation (Class A Stock) trading halted, news pending

06:55 EDT Sanofi says Phase 3 Libtayo combo trial stopped early due to improvement in OS - The Phase 3 trial of Sanofi (SNY) and Regeneron's (REGN) PD-1 inhibitor Libtayo in combination with platinum-doublet chemotherapy was stopped early after meeting its overall survival, or OS, primary endpoint in patients with advanced non-small cell lung cancer, or NSCLC, Sanofi announced. Adding Libtayo to chemotherapy significantly improved OS, compared to chemotherapy alone, in the trial that enrolled patients with metastatic or locally advanced disease and tumors with either squamous or non-squamous histology and across all PD-L1 expression levels. These data are planned to form the basis of regulatory submissions in the U.S. and European Union. The decision to stop the trial early was based on a recommendation by the Independent Data Monitoring Committee during a protocol-specified interim analysis. In this top-line initial analysis of 466 patients, combining Libtayo with chemotherapy reduced the risk of death by 29% compared to chemotherapy alone. Median OS was 22 months for Libtayo and chemotherapy, and 13 months for chemotherapy alone. No new Libtayo safety signals were identified in the IDMC analysis, and additional detailed efficacy and safety data will be presented at an upcoming medical meeting, Sanofi said.

06:50 EDT Regeneron sees FY21 capital expenditures $590M-$640M

06:41 EDT Denbury sees FY sales volume 47,500 BOE/d-51,500 BOE/d - The company has reiterated its 2021 sales volume range for the year of between 47,500 BOE/d and 51,500 BOE/d. Denbury anticipates third quarter sales volumes will increase from the second quarter of 2021, driven primarily by the company's Rocky Mountain region, including the impact from workover projects and continued response from the previous development of Bell Creek Phase 6. Fourth quarter 2021 sales volumes are anticipated to be slightly higher than the third quarter, driven primarily by the company's Gulf Coast Region, where the developments at the Oyster Bayou and Tinsley fields are anticipated to contribute to increased volumes. Development capital expenditures for 2021 are still expected to range from $250 million to $270 million. Third quarter capital expenditures should increase from the second quarter of 2021, primarily due to continued activity supporting the extension of the Greencore CO2 Pipeline and CCA EOR field development. Fourth quarter capital expenditures are anticipated to be relatively consistent with the third quarter of 2021.

06:34 EDT Moderna has started preparing late stage studies for flu vaccine, RSV vaccine

06:33 EDT Moderna board authorizes $1B share repurchase program - The Board of Directors has authorized a share repurchase program of up to $1B over a two-year period to return excess capital to shareholders.

06:31 EDT Moderna's Covid-19 vaccine 93% effective after six months - In final analysis of Phase 3 COVE study data, the Moderna COVID-19 Vaccine showed 93% efficacy, with the efficacy remaining durable through six months after administration of the second dose. "I am proud of the progress our teams at Moderna have made in the past quarter in advancing our development pipeline while addressing a global pandemic and quickly establishing global manufacturing and commercial organizations," said Stephane Bancel, CEO of Moderna. "We now have mRNA candidates in clinical trials across five therapeutic areas including infectious diseases, cardiovascular, oncology, rare disease and autoimmune disorders. We are pleased that our COVID-19 vaccine is showing durable efficacy of 93% through six months, but recognize that the Delta variant is a significant new threat so we must remain vigilant."

06:19 EDT Goodrich Petroleum sees 2H production 165,000-175,000 Mcfe/day in Q3 - The company said, "Second Half of 2021 Guidance has been updated with production expected to average 165,000 - 175,000 Mcfe/day in 3Q21 and 187,500 - 197,500 Mcfe/day in 4Q21, with a mid-point for full year 2021 guidance of 162,000 Mcfe/day. Second half of 2021 cash operating expenses are expected to range between approximately $0.70 - $0.80 per Mcfe and cash interest expense is expected to range between $0.06 - $0.07 per Mcfe for total cash expenses of approximately $0.76 - $0.87 per Mcfe. Capital expenditures are expected to range between $38.0 - $42.0 million in the second half of the year."

06:09 EDT Murphy Oil tightens FY21 production view to 157.5-165.5 MBOEPD - Had seen 155-165 MBOEPD. Sees 2021 CapEx $685M-$715M.

05:42 EDT Hookipa Pharma publishes pre-clinical data on LCMV immunotherapeutic - Hookipa Pharma announced that pre-clinical data on its replicating Lymphocytic choriomeningitis, or LCMV, arenaviral-based immunotherapeutic has been published in the peer-reviewed journal, Nature Communications. The data demonstrate that Hookipa's LCMV-based vector, designed to target melanoma, modulated the tumor microenvironment and induced potent, tumor antigen-specific T cell responses, resulting in tumor regression and tumor cures in a pre-clinical setting. Pre-clinical data featured in the article showed that replicating LCMV-based arenaviral vector administered as a monotherapy led to melanoma tumor regression in all mice, with tumor cures in about 60% of recipients after a single, intra-tumoral administration. Importantly, a single, local injection of the vector into the tumor also led to systemic immune responses, significantly reducing the number of lung metastases. Other key highlights from the paper include findings that Hookipa's single-vector therapy: Modulated the tumor micro-environment, producing a shift towards immune-stimulatory cells; Produced a significant increase in tumor antigen-specific CD8+ T cells, known as killer cells, which are critical for effective tumor control; Reduced T cell exhaustion, resulting in better functional CD8+ T cells within the tumor, as well as more immune-stimulatory CD4+ T cells; Induced long-term memory and protection against melanoma tumor re-challenge; Demonstrated the ability of the arenaviral platform to break tolerance in a difficult-to-treat, poorly immunogenic melanoma model, highlighting the potential of this approach more broadly. Hookipa is evaluating its single-vector and alternating 2-vector technologies in cancer in an ongoing Phase 1/2 clinical trial with HB-201 and HB-202. Each single-vector compound uses a different arenavirus backbone, while expressing the same antigen, an E7E6 fusion protein derived from HPV16. Phase 1 data on HB-200 has shown outstanding CD8+ T cell responses, preliminary efficacy as monotherapy in heavily pre-treated head and neck cancer patients who progressed on standard of care, including checkpoint inhibitors, and favorable tolerability. Hookipa's HB-300 program for prostate cancer also uses the LCMV and PICV arenaviral backbones directed against three validated antigens for prostate cancer: PAP, PSA, and PSMA.

05:12 EDT Amazon announces new, exclusive offers for Prime Student members - Amazon announced new offers exclusively for Prime Student members as students get ready to head to college this fall. Starting immediately, Prime Student members can enjoy exclusive savings including Grubhub+ Student, Calm, StudentUniverse, and Course Hero for a limited time. College students who haven't yet tried Prime Student can sign up for a six-month trial at amazon.com/joinstudent, and then enjoy Prime at half the price for just $6.49 per month or $59 per year.

05:09 EDT Hecla Mining sees FY21 silver production 12.9M-14M ounces - Sees FY21 gold production 191,000-198,000 ounces. Sees FY21 capital expenditures $120M.

04:59 EDT Cathie Wood's Ark Investment bought 2.47M shares of Zymergen - Cathie Wood's Ark Investment Management bought 2.47M shares of Zymergen (ZY) yesterday amid the stock's massive selloff post its business update, according to last night's trading update. Ark also bought 4.14M shares of Soaring Eagle Acquisition (SRNG).